Advertisement

Search Results

Advertisement



Your search for all items matches 1315 pages

Showing 1 - 50


breast cancer

Role of Regulatory T Cells in Predicting Breast Cancer Relapse

Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...

breast cancer
survivorship

Intervention to Promote Breast Cancer Surveillance in Childhood Cancer Survivors Who Received Chest Radiotherapy

In the EMPOWER trial, which took place within the larger Childhood Cancer Survivor Study (CCSS) and was reported in the Journal of Clinical Oncology, Oeffinger et al found that an intervention consisting of mailed educational materials followed by telephone-delivered counseling led to an increased...

breast cancer
issues in oncology

Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?

Findings from a study of patients who received radioactive iodine treatment for hyperthyroidism show a modest association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers at the National Cancer Institute (NCI), was...

breast cancer
survivorship

Mortality After Breast Cancer Among Childhood Cancer Survivors

In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Moskowitz et al found a significant increase in overall mortality among childhood cancer survivors who developed breast cancer vs matched controls. A numeric increase in breast cancer...

breast cancer

Breast Cancer Screening With Addition of MRI to Mammography in Women With Familial Risk

The Dutch FaMRIsc study, reported in The Lancet Oncology by Saadatmand et al, found that the addition of screening magnetic resonance imaging (MRI) to mammography resulted in identification of more breast cancers—and identification at an earlier stage—vs mammography alone among women...

breast cancer

Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

In the French phase III PHARE trial reported in The Lancet, Pivot et al found that noninferiority of 6 months vs 12 months of adjuvant trastuzumab combined with standard chemotherapy could not be demonstrated for disease-free survival in HER2-positive early breast cancer. An earlier interim...

breast cancer
immunotherapy

Niraparib Plus Pembrolizumab in Advanced Triple-Negative Breast Cancer

In the phase II TOPACIO/KEYNOTE-162 trial reported in JAMA Oncology, Vinayak et al found evidence of activity of combined niraparib and pembrolizumab in a cohort of patients with advanced or metastatic triple-negative breast cancer, with higher response rates seen in patients with BRCA mutations or ...

breast cancer
issues in oncology

AACR Environmental Carcinogenesis: Study Finds Environmental Quality Linked With Distant/Metastatic Breast Cancer Risk

Although many risk factors increase a woman’s chance of developing breast cancer—including genetic and hormonal causes—there is increasing evidence suggesting an environmental link. A study investigating the effects of the cumulative environmental quality on aggressive breast...

breast cancer

Personalized Assay May Aid in Determining Risk of Recurrence of Triple-Negative Breast Cancer

Sixty percent of patients with triple-negative breast cancer will survive more than 5 years without disease after standard treatment, but 4 out of 10 women will have a rapid recurrence of the disease. There are currently no clinical tests to assess an individual patient’s prognosis, so all...

breast cancer

PERSEPHONE: 4-Year Disease-Free Survival With 6 vs 12 Months of Adjuvant Trastuzumab for HER2-Positive Breast Cancer

The 4-year disease-free survival results of the UK phase III PERSEPHONE trial, reported by Earl et al in The Lancet, found that 6 months of adjuvant trastuzumab was noninferior to 12 months when given with chemotherapy in HER2-positive early breast cancer. Study Details The open-label trial...

breast cancer
immunotherapy

2019 ASCO: 3-Year Outcomes in the KRISTINE Trial on Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab in HER2-Positive Breast Cancer

As reported at the 2019 ASCO Annual Meeting (Abstract 500) and in the Journal of Clinical Oncology by Hurvitz et al, 3-year outcomes in the phase III KRISTINE trial showed that neoadjuvant trastuzumab emtansine (T-DM1) plus pertuzumab was associated with increased risk of event-free survival events ...

breast cancer
immunotherapy

TONIC: PD-1 Blockade in Metastatic Triple-Negative Breast Cancer

Clinical and translational data from the TONIC trial, published in a research letter by Voorwerk et al in Nature Medicine, indicated that short-term doxorubicin and cisplatin may induce a more favorable tumor microenvironment and increase the likelihood of response to programmed cell death protein...

breast cancer
gastroesophageal cancer
gastrointestinal cancer

FDA Approves New Trastuzumab Biosimilar

Today, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...

breast cancer

2019 ASCO: New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer

New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years of age or younger has emerged from the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx. An analysis of a prespecified secondary endpoint in this trial found that an assessment of a ...

breast cancer
colorectal cancer
health-care policy
issues in oncology

Medicaid Expansion and Colorectal Cancer Screening

A new study examining Medicaid expansion and cancer screening found that the five states and District of Columbia that first adopted Medicaid expansion saw larger increases in colorectal cancer screening than states that did not expand Medicaid. The study—published by Fedewa et al in...

breast cancer

2019 ASCO: Partial- vs Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole-breast irradiation for many women with low-risk, early-stage breast cancer, according to new data from the NRG Oncology/NSABP B-39/RTOG 0413 trial. Results were presented by Ganz et al...

breast cancer

2019 ASCO: MONALEESA-7: Addition of Ribociclib to Endocrine Therapy in Premenopausal Women With HR-Positive, HER2-Negative Breast Cancer

The international, randomized phase III MONALEESA-7 trial found that the addition of ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced hormone receptor (HR)-positive, HER2-negative breast cancer compared with endocrine...

breast cancer

GeparSepto: Long-Term Clinical Outcomes With Neoadjuvant Nab-paclitaxel vs Solvent-Based Paclitaxel in Early Breast Cancer

As reported in the Journal of Clinical Oncology by Untch et al, long-term follow-up in the GeparSepto trial showed that patients with early breast cancer receiving neoadjuvant nab-paclitaxel vs solvent-based paclitaxel followed by epirubicin/cyclophosphamide had better invasive disease–free...

breast cancer

FDA Approves Alpelisib in Combination With Fulvestrant for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

On May 24, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

breast cancer
survivorship

Risk of Subsequent Breast Cancer in Female Childhood Cancer Survivors

As reported by Ehrhardt et al in the Journal of Clinical Oncology, high doses of anthracyclines were associated with increased breast cancer risk in female childhood cancer survivors in the St. Jude Lifetime Cohort Study, with the association being independent of mutations in cancer risk...

breast cancer

Risk of Breast Cancer Among Transgender People

In a Dutch study published by de Blok et al in The BMJ, researchers found an increased risk of breast cancer in transgender women compared with cisgender men, and a lower risk of breast cancer in transgender men than in cisgender women. Methods This retrospective, nationwide cohort study...

breast cancer
lung cancer
issues in oncology

ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers

Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...

breast cancer

Digital Breast Tomosynthesis vs Digital Mammography in a Breast Cancer Screening Program

In a Norwegian study (To-Be) reported in The Lancet Oncology, Hofvind et al found that digital breast tomosynthesis (including synthetic 2D mammograms) did not perform better than standard digital mammography in a population-based breast cancer screening program. Study Details BreastScreen Norway ...

breast cancer
gastroesophageal cancer
gastrointestinal cancer

Trastuzumab Deruxtecan in Advanced HER2-Positive Gastric and Breast Cancers

Two phase I studies reported in The Lancet Oncology indicate activity of the antibody-drug conjugate trastuzumab deruxtecan in advanced HER2-positive gastric cancer and advanced HER2-positive breast cancer previously treated with trastuzumab emtansine (T-DM1). Trastuzumab deruxtecan (DS-8201a) is a ...

breast cancer

2019 ASCO: Low-Fat Diet May Reduce the Risk of Death From Breast Cancer in Postmenopausal Women

Excluding skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. In 2019, the American Cancer Society estimates that about 268,600 new cases of breast cancer will be diagnosed in women, and about 41,760 women will die from their disease. ...

breast cancer

Addition of Tucidinostat to Exemestane in Advanced Hormone Receptor–Positive Breast Cancer

In the Chinese phase III ACE trial reported in The Lancet Oncology, Jiang et al found that the addition of the oral histone deacetylase inhibitor tucidinostat to exemestane improved progression-free survival in postmenopausal women with advanced hormone receptor (HR)-positive breast cancer whose...

breast cancer
lung cancer
skin cancer

Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers

Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...

breast cancer

Sentinel Lymph Node Biopsy With or Without Use of Preoperative Lymphoscintigraphy in Early Breast Cancer

In a German/Swiss phase III trial (SenSzi [GBG80]) reported in the Journal of Clinical Oncology, Kuemmel et al found that preoperative lymphoscintigraphy was not associated with an increased number of histologically detected sentinel lymph nodes with sentinel lymph node biopsy in women with early...

breast cancer

ARRS 2019: Short-Interval Follow-up MRI in Identifying Early-Stage Breast Cancer

When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a study presented by Lamb et al at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting (Abstract 2367). Utilization of ...

breast cancer
solid tumors

FDA Pipeline: Designations in Triple-Negative Breast Cancer, ctDNA Detection

This week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for CCR5-positive metastatic triple-negative breast cancer; granted Breakthrough Device designation to a test for the postsurgical detection and quantification of circulating tumor DNA (ctDNA);...

breast cancer

ASBrS 2019: Comprehensive Postoperative Mastectomy Home Recovery Programs Show Patient Benefit

Comprehensive postoperative mastectomy home recovery programs significantly increased same-day patient discharge with no decrease in quality of care, according to two new studies presented at the Annual Meeting of the American Society of Breast Surgeons (ASBrS). “Research demonstrates the...

breast cancer

Final Analysis of the HannaH Trial: Perioperative Subcutaneous vs Intravenous Trastuzumab in HER2-Positive Early Breast Cancer

As reported in JAMA Oncology by Jackisch et al, the final analysis of the phase III HannaH trial indicated comparable efficacy and safety of perioperative subcutaneous (SC) vs intravenous (IV) trastuzumab in ERBB2 (HER2)-positive early breast cancer. Earlier reports from the trial showed similar...

breast cancer
pain management

ASBrS 2019: Opioid Management Program Reduces Post–Breast Surgery Narcotic Use

A breast surgery opioid prescription management program that analyzed current physician patterns and provided education and guidelines successfully reduced the volume of narcotics given postoperatively to patients at a large institution. These results were presented by Fan et al at the Annual...

breast cancer

ASBrS 2019: Retrospective Study of Nipple-Sparing Mastectomy Outcomes Over Time

Nipple-sparing mastectomy complication and implant failure rates have decreased significantly since introduction of the procedure, while the patient population undergoing nipple-sparing mastectomy increasingly includes more advanced cancers and women traditionally considered at risk for...

breast cancer
symptom management

ASBrS 2019: Bioimpedance Spectroscopy for Surveillance of Breast Cancer–Related Lymphedema

Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy. These were the results of an...

breast cancer

ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer

Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....

breast cancer

FDA Approves Ado-Trastuzumab Emtansine for HER2-Positive Early Breast Cancer

On May 3, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane- and trastuzumab-based treatment. Patients should be...

breast cancer
prostate cancer
symptom management

ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity

The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...

breast cancer

ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer

Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...

breast cancer

ESMO Breast Cancer 2019: Does Continuous Chemotherapy Benefit Patients With Advanced Breast Cancer?

Continuous chemotherapy showed greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented by Erdkamp et al and Claessens et al at the European...

breast cancer

ESMO Breast Cancer 2019: PERNETTA Trial Examines Treatment De-escalation in Women With HER2-Positive Breast Cancer

De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to a European Society for Medical Oncology (ESMO) spokesperson Carmen Criscitiello, MD, PhD, of the European Institute of Oncology in Milan, Italy. Dr. Criscitello commented on the ...

breast cancer

ESMO Breast Cancer 2019: Outcomes in Younger Patients With Breast Cancer

Breast cancer in young women is characterized by more aggressive biologic features as compared to older patients, but outcomes are good when guideline-recommended treatments are given. European Society for Medical Oncology (ESMO) spokesperson Matteo Lambertini, MD, PhD, of IRCCS Policlinico San...

breast cancer

ESMO Breast Cancer 2019: Evidence-Based Educational Nutrition Intervention Among Patients With Early-Stage Breast Cancer

Although tools like the ESPEN guidelines on nutrition for patients with cancer have helped to standardize practices in this area of patient care, scientific evidence on the efficacy of nutritional intervention among patients with breast cancer is still scarce. Preliminary results from a study to be ...

breast cancer
issues in oncology
global cancer care

ESMO Breast Cancer 2019: ONCOLLEGE-001: Global Survey of HER2 Testing

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2-targeted therapies for breast cancer, especially in lower-income countries. These results will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer...

breast cancer

Study Identifies Six Prognostic Factors That May Predict Invasive Breast Cancer Recurrence After a DCIS Diagnosis

Results from a new study are providing information to potentially improve the clinical management of women diagnosed with ductal carcinoma in situ (DCIS). A systematic review with meta-analyses to summarize current knowledge on prognostic factors for invasive disease after a diagnosis of DCIS has...

breast cancer
cost of care

Does Oncotype DX–Guided Treatment Reduce Initial Costs of Breast Cancer Care?

A new study suggests that Oncotype DX–guided treatment could reduce the cost for the first year of breast cancer care in the United States by about $50 million (about 2% of the overall costs in the first year). These findings were published by Mariotto et al in the Journal of the...

breast cancer

Low-Dose Tamoxifen vs Placebo in Preventing Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

In an Italian phase III study reported in the Journal of Clinical Oncology, DeCensi et al found that tamoxifen at 5 mg/d vs placebo for 3 years reduced the risk of recurrence of breast intraepithelial neoplasia and was associated with limited toxicity. As noted by the investigators,...

breast cancer
leukemia
myelodysplastic syndromes

FDA Pipeline: Designations for Myelodysplastic Syndromes, Triple-Negative Breast Cancer, AML, and EBV-Associated Cancers

Over the past week, the U.S. Food and Drug Administration (FDA) granted several Fast Track and Orphan Drug designations to treatments for myelodysplastic syndromes, triple-negative breast cancer, acute myeloid leukemia (AML), and Epstein-Barr virus (EBV)-associated cancers. Fast Track Designation...

breast cancer

Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes

In a long-term follow-up of the Swedish Breast Cancer Group 91 Radiotherapy trial reported in the Journal of Clinical Oncology, Kovács et al found that higher levels of stromal tumor–infiltrating lymphocytes (TILs) and receipt of radiotherapy were independently associated with reduced...

breast cancer

Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors

As reported in the Journal of Clinical Oncology by Tolaney et al, 7-year follow-up of the phase II Adjuvant Paclitaxel and Trastuzumab trial showed that adjuvant paclitaxel and trastuzumab were associated with “excellent” outcomes in women with small, node-negative HER2-positive breast...

Advertisement

Advertisement



;
Advertisement